These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 26856192)

  • 1. The generalizability of bronchiectasis randomized controlled trials: A multicentre cohort study.
    Chalmers JD; McDonnell MJ; Rutherford R; Davidson J; Finch S; Crichton M; Dupont L; Hill AT; Fardon TC; De Soyza A; Aliberti S; Goeminne P
    Respir Med; 2016 Mar; 112():51-8. PubMed ID: 26856192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis.
    Bilton D; Daviskas E; Anderson SD; Kolbe J; King G; Stirling RG; Thompson BR; Milne D; Charlton B;
    Chest; 2013 Jul; 144(1):215-225. PubMed ID: 23429964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.
    Bilton D; Tino G; Barker AF; Chambers DC; De Soyza A; Dupont LJ; O'Dochartaigh C; van Haren EH; Vidal LO; Welte T; Fox HG; Wu J; Charlton B;
    Thorax; 2014 Dec; 69(12):1073-9. PubMed ID: 25246664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients enrolled in randomised clinical trials are not representative of critically ill patients in clinical practice: observational study focus on tigecycline.
    Zimmermann JB; Horscht JJ; Weigand MA; Bruckner T; Martin EO; Hoppe-Tichy T; Swoboda S
    Int J Antimicrob Agents; 2013 Nov; 42(5):436-42. PubMed ID: 24055255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: meta-analysis of randomized controlled trials.
    Zhuo GY; He Q; Xiang-Lian L; Ya-Nan Y; Si-Te F
    Pulm Pharmacol Ther; 2014 Oct; 29(1):80-8. PubMed ID: 24594263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
    Zink A; Strangfeld A; Schneider M; Herzer P; Hierse F; Stoyanova-Scholz M; Wassenberg S; Kapelle A; Listing J
    Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled mannitol in the treatment of non-cystic fibrosis bronchiectasis in adults.
    Gjoerup J; Hilberg O; Bendstrup E
    Respirology; 2012 Aug; 17(6):927-32. PubMed ID: 22564014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization.
    Hordijk-Trion M; Lenzen M; Wijns W; de Jaegere P; Simoons ML; Scholte op Reimer WJ; Bertrand ME; Mercado N; Boersma E;
    Eur Heart J; 2006 Mar; 27(6):671-8. PubMed ID: 16423872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential outcomes after sirolimus-eluting stent implantation: comparing on-label versus off-label patients in the 'real world'.
    Jeremias A; Ruisi CP; Kirtane AJ; Lee T; Sylvia B; Pinto DS; Ho KK; Cutlip DE; Carrozza JP; Cohen DJ
    Coron Artery Dis; 2008 Mar; 19(2):111-5. PubMed ID: 18300748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatment options for bronchiectasis.
    Metersky ML
    Ther Adv Respir Dis; 2010 Apr; 4(2):93-9. PubMed ID: 20388725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials?
    Scichilone N; Basile M; Battaglia S; Bellia V
    Respiration; 2014; 87(1):11-7. PubMed ID: 24281343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.
    Garcia-Doval I; Carretero G; Vanaclocha F; Ferrandiz C; Daudén E; Sánchez-Carazo JL; Alsina M; Herrera-Ceballos E; Gómez-García FJ; Ferrán M; López-Estebaranz JL; Hernanz JM; Belinchón-Romero I; Vilar-Alejo J; Rivera R; Carrascosa JM; Carazo C
    Arch Dermatol; 2012 Apr; 148(4):463-70. PubMed ID: 22508869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: a retrospective observational study.
    Coeman M; van Durme Y; Bauters F; Deschepper E; Demedts I; Smeets P; Joos G; Brusselle G
    Ther Adv Respir Dis; 2011 Dec; 5(6):377-86. PubMed ID: 21890536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial therapy for bronchiectasis.
    O'Donnell AE
    Clin Chest Med; 2012 Jun; 33(2):381-6. PubMed ID: 22640853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bronchiectasis: which antibiotics to use and when?
    O'Donnell AE
    Curr Opin Pulm Med; 2015 May; 21(3):272-7. PubMed ID: 25764019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium cromoglycate and eformoterol attenuate sensitivity and reactivity to inhaled mannitol in subjects with bronchiectasis.
    Briffa PJ; Anderson SD; Burton DL; Young IH
    Respirology; 2011 Jan; 16(1):161-6. PubMed ID: 21054671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials.
    Yuen SY; Pope JE
    Rheumatology (Oxford); 2008 Sep; 47(9):1367-72. PubMed ID: 18577549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-cystic fibrosis bronchiectasis: an evidence-base for new therapies.
    Bilton D; Loebinger MR; Wilson R
    Lancet Respir Med; 2014 Dec; 2(12):958-60. PubMed ID: 25466345
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhaled antibiotics in Cystic Fibrosis (CF) and non-CF bronchiectasis.
    Tay GT; Reid DW; Bell SC
    Semin Respir Crit Care Med; 2015 Apr; 36(2):267-86. PubMed ID: 25826593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic options for noncystic fibrosis bronchiectasis.
    Yap VL; Metersky ML
    Curr Opin Infect Dis; 2015 Apr; 28(2):171-6. PubMed ID: 25692269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.